A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Trial Profile

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Evofosfamide (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Therapeutic Use
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 22 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top